These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17622394)

  • 1. Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
    Tu JV
    Can J Cardiol; 2007 Jul; 23(9):719-20. PubMed ID: 17622394
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.
    LeLorier J; Rawson NS
    Can J Cardiol; 2007 Jul; 23(9):711-8. PubMed ID: 17622393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational use of medications: if Canada can't do it ..
    Califf RM
    CMAJ; 2009 Jul; 181(1-2):15-6. PubMed ID: 19581612
    [No Abstract]   [Full Text] [Related]  

  • 4. Medication adherence: a call for action.
    Bosworth HB; Granger BB; Mendys P; Brindis R; Burkholder R; Czajkowski SM; Daniel JG; Ekman I; Ho M; Johnson M; Kimmel SE; Liu LZ; Musaus J; Shrank WH; Whalley Buono E; Weiss K; Granger CB
    Am Heart J; 2011 Sep; 162(3):412-24. PubMed ID: 21884856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
    Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
    Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacoeconomics and cardiovascular disease].
    Anguita Sánchez M
    Rev Clin Esp; 2004 Aug; 204(8):391-2. PubMed ID: 15274760
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 9. Orphan Drug Development in Cardiovascular Medicine.
    Khan MS; Vaduganathan M; Butler J
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006509. PubMed ID: 32552063
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
    Shantsila A; Lip GY
    Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 13. [Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
    Wehling M
    Dtsch Med Wochenschr; 2004 Feb; 129(7):330. PubMed ID: 14765334
    [No Abstract]   [Full Text] [Related]  

  • 14. The Imminent Demise of Cardiovascular Drug Development.
    Packer M
    JAMA Cardiol; 2017 Dec; 2(12):1293-1294. PubMed ID: 29117286
    [No Abstract]   [Full Text] [Related]  

  • 15. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 16. Associations between essential medicines and health outcomes for cardiovascular disease.
    Steiner L; Fraser S; Maraj D; Persaud N
    BMC Cardiovasc Disord; 2021 Mar; 21(1):151. PubMed ID: 33765933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficiaries with cardiovascular disease and thePart D coverage gap.
    Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S
    Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

  • 19. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.